Dynamics of a Nosocomial Outbreak of Multidrug-Resistant Pseudomonas aeruginosa Producing the PER-1 Extended-Spectrum β-Lactamase
暂无分享,去创建一个
A. Orsatti | V. Orlandi | G. Rossolini | F. Luzzaro | G. Lombardi | A. Toniolo | G. Amicosante | M. Perilli | E. Mantengoli
[1] S. Lory,et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen , 2000, Nature.
[2] M. Vaneechoutte,et al. PER-1 β-lactamase-producing Pseudomonas aeruginosa in an intensive care unit , 2000 .
[3] L. Bush,et al. Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations. , 2000, Infectious disease clinics of North America.
[4] C. Gentry,et al. Increasing antimicrobial resistance in gram-negative bacilli isolated from patients in intensive care units. , 2000, American journal of infection control.
[5] G. Cornaglia,et al. Carbapenem-resistant Pseudomonas aeruginosa with acquired bla(vim) metallo-beta-lactamase determinants, Italy. , 2000, Emerging infectious diseases.
[6] J. Verhoef,et al. Antimicrobial Resistance in European Isolates of Pseudomonas aeruginosa , 2000, European Journal of Clinical Microbiology and Infectious Diseases.
[7] N. Woodford,et al. Outbreak of Infections Caused by Pseudomonas aeruginosa Producing VIM-1 Carbapenemase in Greece , 2000, Journal of Clinical Microbiology.
[8] D. Sirot,et al. Production of a TEM-24 Plasmid-Mediated Extended-Spectrum β-Lactamase by a Clinical Isolate ofPseudomonas aeruginosa , 2000, Antimicrobial Agents and Chemotherapy.
[9] P. Nordmann,et al. Extended-spectrum β-lactamase TEM-4 in Pseudomonas aeruginosa. , 1999, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[10] H. Sader,et al. Nosocomial Infections Caused by Multiresistant Pseudomonas aeruginosa , 1999, Infection Control & Hospital Epidemiology.
[11] D. Michael Olive,et al. Principles and Applications of Methods for DNA-Based Typing of Microbial Organisms , 1999, Journal of Clinical Microbiology.
[12] E. Bouza,et al. Pseudomonas aeruginosa: a Survey of Resistance in 136 Hospitals in Spain , 1999, Antimicrobial Agents and Chemotherapy.
[13] T. Köhler,et al. Patterns and modes of β-lactam resistance in Pseudomonas aeruginosa , 1999 .
[14] M. Gründling,et al. A large outbreak of multiresistant Pseudomonas aeruginosa strains in north-eastern Germany. , 1999, The Journal of antimicrobial chemotherapy.
[15] H. Domdey,et al. Safety and Immunogenicity of a Pseudomonas aeruginosa Hybrid Outer Membrane Protein F-I Vaccine in Human Volunteers , 1999, Infection and Immunity.
[16] L E Nilsson,et al. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. , 1999, JAMA.
[17] A. D. Russell,et al. Antiseptics and Disinfectants: Activity, Action, and Resistance , 1999, Clinical Microbiology Reviews.
[18] P. Nordmann,et al. Extended-spectrum beta-lactamases in Pseudomonas aeruginosa. , 1998, The Journal of antimicrobial chemotherapy.
[19] R. Hancock. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] H. Vahaboğlu,et al. Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp. , 1998, The Journal of antimicrobial chemotherapy.
[21] W. Traub,et al. Surveillance of Pseudomonas aeruginosa in Intensive Care Units: Clusters of Nosocomial Cross-Infection and Encounter of a Multiple-Antibiotic Resistant Strain , 1998, Chemotherapy.
[22] G. Bonfiglio,et al. Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey. , 1998, The Journal of antimicrobial chemotherapy.
[23] H. Leblebicioglu,et al. Widespread Detection of PER-1-Type Extended-Spectrum β-Lactamases among NosocomialAcinetobacter and Pseudomonas aeruginosaIsolates in Turkey: a Nationwide Multicenter Study , 1998, Antimicrobial Agents and Chemotherapy.
[24] H. Leblebicioglu,et al. Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study , 1997, Antimicrobial agents and chemotherapy.
[25] M. Rué,et al. Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] D. Livermore. beta-Lactamases in laboratory and clinical resistance , 1995, Clinical microbiology reviews.
[27] D. Livermore,et al. Resistance to extended-spectrum cephalosporins, caused by PER-1 beta-lactamase, in Salmonella typhimurium from Istanbul, Turkey. , 1995, Journal of medical microbiology.
[28] D H Persing,et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.
[29] J. Vincent,et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. , 1995, JAMA.
[30] G. Jacoby,et al. A functional classification scheme for beta-lactamases and its correlation with molecular structure , 1995, Antimicrobial agents and chemotherapy.
[31] D. Livermore,et al. Transferable production of PER-1 β-lactamase in Pseudomonas aeruginosa , 1995 .
[32] P. Nordmann,et al. Sequence analysis of PER-1 extended-spectrum beta-lactamase from Pseudomonas aeruginosa and comparison with class A beta-lactamases , 1994, Antimicrobial Agents and Chemotherapy.
[33] P. Nordmann,et al. Characterization of a novel extended-spectrum beta-lactamase from Pseudomonas aeruginosa , 1993, Antimicrobial Agents and Chemotherapy.
[34] J. Lupski,et al. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. , 1991, Nucleic acids research.
[35] J R Roth,et al. Ability of a bacterial chromosome segment to invert is dictated by included material rather than flanking sequence. , 1991, Genetics.
[36] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.
[37] S. Lory,et al. Complete genome sequence of Pseudomonas aeruginosa PAO 1 , an opportunistic pathogen , 2000 .
[38] G. Rossolini,et al. PER-1 extended-spectrum beta-lactamase production in an Alcaligenes faecalis clinical isolate resistant to expanded-spectrum cephalosporins and monobactams from a hospital in Northern Italy. , 2000, Microbial drug resistance.
[39] Mary Jane Ferraro,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .
[40] D. Livermore,et al. Transferable production of PER-1 beta-lactamase in Pseudomonas aeruginosa. , 1995, The Journal of antimicrobial chemotherapy.
[41] J. Waitz. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .
[42] John E. Bennett,et al. Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .